DaVita Inc. (DVA)
After hours:
| Previous Close | 92.34 |
| Open | 92.20 |
| Bid | 91.20 x 900 |
| Ask | 94.20 x 900 |
| Day's Range | 92.18 - 93.61 |
| 52 Week Range | 74.97 - 133.88 |
| Volume | |
| Avg. Volume | 1,028,180 |
| Market Cap | 8.484B |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | 11.51 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Medtronic and DaVita announce new kidney health technology company
Medtronic plc (NYSE:MDT) and DaVita Inc. (NYSE:DVA) today announced the intent to form a new, independent kidney care-focused medical device company ("NewCo" or "the Company") to enhance the patient treatment experience and improve overall outcomes.
- GlobeNewswire
Miromatrix to Ring Nasdaq Closing Bell on National Donor Day, February 14, 2022
EDEN PRAIRIE, Minn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that the Company will ring the closing bell at Nasdaq on Monday, February 14, 2022, at 4:00 p.m. ET to celebrate National Donor Day and the Company’s public listing last year on Nasdaq under the trading symbol MIRO. Miromatrix CEO, Jeff Ross, Ph.D., wi
- GlobeNewswire
Renalytix Reports Full Year Fiscal 2021 Results
LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its results for the twelve months ended 30 June 2021. Highlights: Regulatory & Reimbursement Government-wide contract granted by the U.S. General Services Administration for KidneyIntelX™ testing s
